2 days Ago By Defense World Staff
KLP Kapitalforvaltning AS bought a new stake in Fulgent Genetics, Inc. ( NASDAQ:FLGT – Free Report ) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,100 shares of the company’s stock, valued at approximately $57,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in Fulgent Genetics by 45.5% in the 4th quarter.
GAMMA Investing LLC now owns 2,133 shares of the company’s stock valued at $39,000 after buying an additional 667 shares during the last quarter. R Squared Ltd bought a new stake in shares of Fulgent Genetics during the fourth quarter worth approximately $74,000. Amundi increased its position in Fulgent Genetics by 143.
7% during the 4th quarter. Amundi now owns 8,816 shares of the company’s stock worth $166,000 after buying an additional 5,199 shares during the period. Wealthspire Advisors LLC bought a new stake in shares of Fulgent Genetics in the fourth quarter valued at about $186,000.
Finally, Quantbot Technologies LP grew its stake in shares of Fulgent Genetics by 131.9% in the fourth quarter. Quantbot Technologies LP now owns 10,420 shares of the company’s stock valued at $192,000 after acquiring an additional 5,926 shares in the last quarter.
48.06% of the stock is currently owned by institutional investors. Analyst Ratings Changes A number of research analysts have issued reports on FLGT shares.
StockNews.com upgraded shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 5th. Piper Sandler dropped their price target on Fulgent Genetics from $22.
00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Fulgent Genetics Price Performance Shares of FLGT opened at $19.
00 on Friday. The firm has a 50 day simple moving average of $16.91 and a two-hundred day simple moving average of $18.
30. Fulgent Genetics, Inc. has a one year low of $14.
57 and a one year high of $25.11. The company has a market cap of $586.
45 million, a P/E ratio of -3.44 and a beta of 1.36.
Insider Buying and Selling at Fulgent Genetics In other Fulgent Genetics news, CFO Paul Kim bought 100,000 shares of the stock in a transaction on Wednesday, March 5th. The stock was acquired at an average cost of $15.96 per share, for a total transaction of $1,596,000.
00. Following the completion of the acquisition, the chief financial officer now owns 348,282 shares in the company, valued at $5,558,580.72.
This trade represents a 40.28 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link .
Corporate insiders own 31.76% of the company’s stock. Fulgent Genetics Company Profile ( Free Report ) Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Featured Articles Five stocks we like better than Fulgent Genetics EV Stocks and How to Profit from Them JPMorgan is a Buy, if You Can Handle The Volatility What is Short Interest? How to Use It United States Steel’s Crash: An Unmissable Buying Opportunity Dividend Screener: How to Evaluate Dividend Stocks Before Buying Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding FLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulgent Genetics, Inc.
( NASDAQ:FLGT – Free Report ). Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter .
.
